Supernus Pharmaceuticals (SUPN) Receivables - Other (2012 - 2026)

Supernus Pharmaceuticals (SUPN) has 6 years of Receivables - Other data on file, last reported at $1.9 million in Q1 2026.

• Receivables - Other for Q1 2026 came in at $1.9 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $1.9 million (changed N/A YoY), and the FY2025 annual result was $1.8 million, down 55.0% from the prior year.
• Receivables - Other rose to $1.9 million in Q1 2026 per SUPN's latest filing, from $1.8 million in the prior quarter.
• Over five years, Receivables - Other peaked at $6.3 million in Q3 2025 and troughed at $1.8 million in Q4 2025.
• A 3-year average of $3.9 million and a median of $4.0 million in 2024 frame the typical range for Receivables - Other.
• On a YoY basis, Receivables - Other climbed as much as 55.0% in 2025 and fell as far as 55.0% in 2025.
• A 3-year view of Receivables - Other shows it stood at $4.0 million in 2024, then plunged by 55.0% to $1.8 million in 2025, then increased by 5.56% to $1.9 million in 2026.
• Business Quant data shows SUPN's Receivables - Other at $1.9 million in Q1 2026, $1.8 million in Q4 2025, and $6.3 million in Q3 2025.